Wishing you all the joys of the season! 
South & Central America Antibody Drug Conjugates Market Forecast to 2030
South & Central America Antibody Drug Conjugates Market Forecast to 2030 – Regional Analysis – By Technology (Cleavable Linker and Non-cleavable Linker), Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Urothelial Cancer, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Escalating Pipeline of ADCs Fuels the South & Central America Antibody Drug Conjugates Market
Various biopharmaceutical companies are developing ADCs owing to the rising interest in ADCs as promising cancer treatment. Companies such as ImmunoGen, Inc; NBE-Therapeutics, Seagen Inc; ADC Therapeutics; Merck KGaA; Sorrento Therapeutics, Inc; Mythic Therapeutics; Sutro Biopharma; Peak Bio; Regeneron Pharmaceuticals; Asana BioSciences; Sanofi; Navrogen, Inc; and OBI Pharma have ADCs in the different developmental phases. It is anticipated that the commercial launch of the ADCs developed will significantly enhance market size.
The companies have developed a broad list of promising ADCs in the different clinical stages and pipelines to be commercialized. The list of ADCs in the pipeline includes Camidanlumab tesirine, ADCT-602, Zynlonta, ADCT-901, ADCT-701, ADCT-212, ADCT-601, Ladiratuzumab Vedotin, NBE-002, IMGN151, IMGN-632, IMGC 936, IMGN-151, OBI 999, R 992, NAV-001, MYTX-011, M1231, STI-6129, Torpedo, BCMA ADC, REGN5093-M114, ASN004, TR 1801 ADC.
Companies have also shared pre-clinical data related to their respective products. For instance, in April 2023, Mythic Therapeutics announced preclinical data for its MYTX-011 (cMET-targeting ADC). The data published included the highlights of MYTX-011 intended to treat a broad range of cMET+ cancers. Likewise, at the Association for Cancer Research Annual Meeting in April 2023, Araris Biotech AG announced its preclinical data on anti-Nectin-4 and anti-HER2 ADCs. The two ADCs were developed using the company’s proprietary linker technology. The data demonstrated improved anti-tumor activity of anti-Nectin-4 and anti-HER2 ADCs compared to respective FDA-approved ADCs in head-to-head in-vivo studies. Thus, the rise in innovative ADCs will likely propel the market growth exponentially in the coming years.
South & Central America Antibody Drug Conjugates Market Overview
The antibody drug conjugates market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. The market growth in this region is primarily attributed increasing awareness regarding cancer screening. For instance, the Brazilian Association of Intestinal Cancer Prevention (ABRAPRECI) and the Colorectal Cancer Prevention and Screening Program have been initiated to create awareness among the masses. The growth in awareness campaigns and screening programs has increased the demand for colonoscopy services. In addition, in December 2020, a French diagnostic firm, HalioDx signed an agreement with Diagnosticos da America (DASA) to distribute its Immunoscore colon cancer risk-assessment test in Brazil. Immunoscore assists in predicting the risk of relapse in early-stage colon cancer by measuring host immune responses at tumor sites, which helps plan treatment strategies. Under the agreement terms, in Brazil, Sao Paulo-based DASA has exclusive distribution rights to the test, offering it through 40 laboratory networks. As ADCs target specific cancer cells and release toxic drug into the cancer cells, the rising cases of cancer in the country are expected to boost the market in the future. Also, the current plans for colorectal cancer screening in Argentina, the incidence of colorectal cancer is expected to increase shortly due to the discovery of previously undiagnosed diseases. Therefore, these factors are likely to contribute to the progress of the antibody drug conjugates market in Argentina during the forecast period.
South & Central America Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Antibody Drug Conjugates Market Segmentation
The South & Central America antibody drug conjugates market is segmented based on technology, application, distribution channel, and country.
Based on technology, the South & Central America antibody drug conjugates market antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held a larger share in 2022.
Based on application, the South & Central America antibody drug conjugates market antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held the largest share in 2022.
Based on distribution channel, the South & Central America antibody drug conjugates market antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share in 2022.
Based on country, the South & Central America antibody drug conjugates market is categorized into Brazil, Argentina, the Rest of South & Central America. Brazil dominated the South & Central America antibody drug conjugates market in 2022.
Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, and Takeda Pharmaceutical Co Ltd are some of the leading companies operating in the South & Central America antibody drug conjugates market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the South & Central America antibody drug conjugates market was valued at US$ 264.91 million in 2022 and is expected to reach US$ 799.23 million by 2030, registering a CAGR of 14.8% from 2022 to 2030. Increasing investments to develop ADCs and increasing FDA approvals are among the critical factors attributed to the South & Central America antibody drug conjugates market expansion.
Developing products in the biopharmaceutical industry requires huge investments. ADCs are novel products that consume a long period for development, clinical trials, approvals, and commercialization. Developing a new molecule or product requires a minimum of 12 years with an investment of ~US$ 1-2 billion. There is an additional cost for regulatory procedures, as stringent regulations for new product development exist. Therefore, the cost of commercialized ADCs is considerably high; in most cases, they are not reimbursed. For instance, in November 2022, Immunogen announced that it would sell its drug conjugate, Elahere (mirvetuximab soravtansine), for US$ 6,220 per vial to treat ovarian cancer in adults. Immunogen also revealed that many patients will receive three to four vials of Elahere between US$ 18,500 and US$ 25,000/cycle. Elanhere is administered once in the 21-day treatment cycle. Similarly, Trodelvy, a breast cancer drug from Gilead, costs US$ 2,188 per vial. Trodelvy is given twice in the 21-day treatment cycle, and 10 mg/kg dosage is recommended based on the patients weight. Thus, the high cost of ADC development notably affects the cost of commercialization, and the dosage variation according to the patients weight hinders market growth.
On the contrary, high cost of ADCs development and commercialization hampers the growth South & Central America antibody drug conjugates market.
Based on technology, the South & Central America antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held 68.6% share of the South & Central America antibody drug conjugates market in 2022, amassing US$ 181.74 million. It is projected to garner US$ 541.21 million by 2030 to expand at 14.6% CAGR during 2022-2030.
Based on application, the South & Central America antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held 57.6% share of the South & Central America antibody drug conjugates market in 2022, amassing US$ 152.62 million. It is projected to garner US$ 473.93 million by 2030 to expand at 15.2% CAGR during 2022-2030.
Based on distribution channel, the South & Central America antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 70.3% share of South & Central America antibody drug conjugates market in 2022, amassing US$ 186.10 million. It is projected to garner US$ 575.45 million by 2030 to expand at 15.2% CAGR during 2022-2030.
Based on country, the South & Central America antibody drug conjugates market is categorized into Brazil, Argentina, the Rest of South & Central America. Brazil held 84.6% share of South & Central America antibody drug conjugates market in 2022, amassing US$ 223.98 million. It is projected to garner US$ 687.33 million by 2030 to expand at 15.0% CAGR during 2022-2030.
Key players operating in the South & Central America antibody drug conjugates market are Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, and Takeda Pharmaceutical Co Ltd, among others.
– In Mar 2023, Pfizer Inc. and Seagen Inc entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.
– In Sept 2023, Seagen Inc., a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. This collaboration leverages Seagens world-class expertise and knowledge of ADC development, manufacturing, and commercialization to maximize the potential of disitamab vedotin.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in South & Central America antibody drug conjugates market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Antibody Drug Conjugates Market – Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
4.1.2 Rising Incidences of Cancer Cases
4.1.3 Increasing FDA Approvals for ADCs
4.2 Market Restraints
4.2.1 High Cost of ADCs Development and Commercialization
4.3 Market Opportunities
4.3.1 Increasing Investments to Develop ADCs
4.4 Market Trends
4.4.1 Escalating Pipeline of ADCs
4.5 Impact Analysis:
5. Antibody Drug Conjugates Market – South & Central America Market Analysis
5.1 South & Central America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 – 2030
6. South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Technology
6.1 Overview
6.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
6.3 Cleavable Linker
6.3.1 Overview
6.3.2 Cleavable Linker: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Non-cleavable Linker
6.4.1 Overview
6.4.2 Non-cleavable Linker: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Application
7.1 Overview
7.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Blood Cancer
7.3.1 Overview
7.3.2 Blood Cancer: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Breast Cancer
7.4.1 Overview
7.4.2 Breast Cancer: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Ovarian Cancer
7.5.1 Overview
7.5.2 Ovarian Cancer: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Urothelial Cancer
7.6.1 Overview
7.6.2 Urothelial Cancer: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Antibody Drug Conjugates Market – Country Analysis
9.1 South & Central America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 South & Central America Antibody Drug Conjugates Market Breakdown, by Country- Revenue (2022) (US$ Million)
9.1.3 South & Central America: Antibody Drug Conjugates Market, by Countries, 2022 and 2030 (%)
9.1.3.1 Brazil
9.1.3.1.1 Overview
9.1.3.1.2 Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.3 Brazil: Antibody Drug Conjugates Market, by Technology
9.1.3.1.4 Brazil: Antibody Drug Conjugates Market, by Application
9.1.3.1.5 Brazil: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.2 Argentina
9.1.3.2.1 Overview
9.1.3.2.2 Argentina: Antibody Drug Conjugates Market, by Technology
9.1.3.2.3 Argentina: Antibody Drug Conjugates Market, by Application
9.1.3.2.4 Argentina: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.3 Rest of South & Central America
9.1.3.3.1 Overview
9.1.3.3.2 Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.3 Rest of South & Central America: Antibody Drug Conjugates Market, by Technology
9.1.3.3.4 Rest of South & Central America: Antibody Drug Conjugates Market, by Application
9.1.3.3.5 Rest of South & Central America: Antibody Drug Conjugates Market, by Distribution Channel
10. Antibody Drug Conjugates Market-Industry Landscape
10.1 Overview
10.2 Organic Growth Strategies
10.2.1 Overview
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Companies’ Manufacturing Capacities and Capabilities
11. Company Profiles
11.1 Pfizer Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Hoffmann-La Roche Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GSK Plc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Gilead Sciences Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 AstraZeneca Plc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Astellas Pharma Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Takeda Pharmaceutical Co Ltd
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
LIST OF TABLES
Table 1. South & Central America Antibody Drug Conjugates Market Segmentation
Table 2. New Cancer Cases Worldwide, in 2020
Table 3. List of FDA-Approved ADCs
Table 4. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 5. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 6. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 7. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 8. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 9. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 10. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 11. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 12. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 13. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 14. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 15. Glossary of Terms, Antibody Drug Conjugates Market
LIST OF FIGURES
Figure 1. South & Central America Antibody Drug Conjugates Market Segmentation, By Country
Figure 2. Key Insights
Figure 3. South & Central America Antibody Drug Conjugates Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. South & Central America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 – 2030
Figure 6. South & Central America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Cleavable Linker: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Non-Cleavable Linker: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. South & Central America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 10. Blood Cancer: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Breast Cancer: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Ovarian Cancer: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Urothelial Cancer: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. South & Central America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 16. Hospital Pharmacies: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Retail Pharmacies: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Online Pharmacies: South & Central America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. South & Central America Antibody Drug Conjugates, by Key Country – Revenue (2022) (US$ Million)
Figure 20. South & Central America: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 21. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
The List of Companies – South & Central America Antibody Drug Conjugates Market
1. Pfizer Inc
2. Hoffmann-La Roche Ltd
3. GSK Plc
4. Gilead Sciences Inc
5. AstraZeneca Plc
6. Astellas Pharma Inc
7. Takeda Pharmaceutical Co Ltd
You must be logged in to post a review.
Reviews
There are no reviews yet.